GlassScriptPhysician profile
Karl G Rose
NPI 1235136029
$9,631.88
in general payments reported to CMS, 2019-2025
33 companies · $682 in 2025
The $682 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,516 · 2020: $1,363 · 2021: $1,870 · 2022: $1,457 · 2023: $1,594 · 2024: $1,150 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,425.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,252.28 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $1,146.42 | 2019-2025 | |
| Abbott Laboratories | $867.04 | 2020-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $721.39 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $700.05 | 2019-2024 | Tradjenta, Jardiance, Stiolto Respimat |
| Lilly USA, LLC | $640.12 | 2019-2025 | Mounjaro |
| Abbvie INC. | $513.09 | 2020-2024 | Qulipta, Vraylar, Ubrelvy |
| Astellas Pharma US INC | $471.75 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $371.00 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $344.29 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $204.54 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $188.63 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $160.68 | 2019-2023 | |
| Esperion Therapeutics, INC. | $135.09 | 2020-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $124.70 | 2019-2023 | Camzyos |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $96.95 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.62 | 2022-2023 | |
| Almatica Pharma LLC | $64.81 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $60.06 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.35 | 2023-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $54.82 | 2024-2025 | Voquezna |
| Renalytix Ai, INC. | $51.47 | 2022-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Xeris Pharmaceuticals, INC. | $49.36 | 2022-2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $49.12 | 2023 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $41.66 | 2019 | |
| Amarin Pharma, INC. | $39.58 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $38.55 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.65 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $19.24 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.70 | 2022 | |
| Pulmonx Corporation | $12.78 | 2022 | |
| Allergan, INC. | $11.77 | 2020 | |
| Vanda Pharmaceuticals INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.